Virtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Miyeon Jung, PhD, RN
- Phone Number: 317-274-4360
- Email: miyjung@iu.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
We will use a two-step process to screen and enroll the patients. First, we will screen potentially eligible patients from the Indiana University Health systems using these eligibility criteria.
Inclusion Criteria:
- ≥ 55 years;
- chronic HF Stage C validated from echocardiography or comparable measure or B-type natriuretic peptide (BNP) level > 400 pg/ml [or equivalent NT-proBNP] in past 3 years;
- ability to communicate in English;
- capacity to consent according to the Indiana University Institutional Review Board policies, or lacks capacity to consent but has the ability to provide assent from someone who can serve as LAR; and
- Subjectively reported cognitive concern assessed by the question, "Do you have any trouble with your memory or thinking?".
Exclusion Criteria:
- pre-HF (Stages A and B) or advanced HF (Stage D);
- vision or hearing problems that can interfere with cognitive testing;
- major neurological disorder (e.g., previously diagnosed dementia, Parkinson's disease, epilepsy, multiple sclerosis);
- major psychiatric disease (e.g., schizophrenia, bipolar disorder);
- life-threatening unstable illness other than HF (e.g., end-stage cancer); and
- users of regular computerized cognitive training or participants in cognitive training trials in the past year.
Second, we will enroll patients only if they have MCI or normal cognition by not meeting criteria for dementia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vita (virtual reality-based cognitive restoration intervention)
Participants randomized to Vita will receive a virtual reality head-mount device (e.g., Oculus Quest) to view nature pictures for 10 minutes (1 set of 10 pictures)/day, 2-3 days/week for 8 weeks (a total of 20 sets for 200 minutes, approximately 3.3 hours) based on the provided activity schedule.
Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
|
Vita is developed by this study team based on Attention Restoration Theory.
The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
|
|
Experimental: Com (computerized cognitive training intervention )
Participants randomized to Com will receive a tablet computer (e.g., iPad) to complete BrainHQ training for 1 hour (6 exercises)/day, 2-3 days/week for 8 weeks (total of 20 hours) based on the provided activity schedule.
Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
|
Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity.
The com intervention involves doing game-like training on a iPad.
|
|
Experimental: Vita+Com (Both Vita and Com intervention)
Participants randomized to Vita+Com will receive both Vita and Com simultaneously.
They will spend 10 minutes on Vita and then 1 hour on Com per day, 2-3 days/week for 8 weeks (a total of 23.3 hours).
Participants will receive weekly check-in calls from the intervention RA during the 8 weeks of intervention phase.
|
Vita+Com intervention is a combination of both Vita and Com interventions.
Participants will be asked to complete Vita first and then Com intervention.
|
|
No Intervention: Usual care
Participants randomized to this control condition will continue to receive their usual care, but no interventions from the study team.
We will monitor changes in their activities that may affect changes in cognitive function (e.g., starting book clubs) by weekly check-in calls during the 8 weeks of intervention phase.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in cognitive function: attention
Time Frame: Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
Trail Making and Number Span Test from National Alzheimer's Coordinating Center Neuropsychological battery (Uniform Data Set V3.0)
|
Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
|
Changes in cognitive function: memory
Time Frame: Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
Craft Story 21 and Benson Figure Copy for memory from National Alzheimer's Coordinating Center Neuropsychological battery (Uniform Data Set V3.0)
|
Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in heart failure self-care
Time Frame: Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
Self-Care of Heart Failure Index
|
Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
|
Changes in instrumental activities of daily living
Time Frame: Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
Functional Activities Questionnaire (for both patients and informants)
|
Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
|
Changes in instrumental activities of daily living
Time Frame: Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
Everyday Problems Test (performance-based, for patient only)
|
Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
|
Changes in health-related quality of life
Time Frame: Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
Minnesota Living with Heart Failure Questionnaire
|
Baseline, 8 weeks, 16 weeks, and 1 year (52 weeks) after baseline
|
|
Dementia-free survival
Time Frame: 1 year after baseline
|
Survival status (alive or deceased) at year collected from electronic health records
|
1 year after baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Mental Disorders
- Heart Diseases
- Neurocognitive Disorders
- Cognition Disorders
- Heart Failure
- Cognitive Dysfunction
- Sulfur Compounds
- Organic Chemicals
- Retinoids
- Carotenoids
- Polyenes
- Alkenes
- Hydrocarbons, Acyclic
- Hydrocarbons
- Cyclohexenes
- Cyclohexanes
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Pigments, Biological
- Biological Factors
- Diterpenes
- Alkanes
- Alkanesulfonates
- Alkanesulfonic Acids
- Sulfonic Acids
- Sulfur Acids
- Sulfhydryl Compounds
- Mesna
- Vitamin A
Other Study ID Numbers
Other Study ID Numbers
- 15739
- 1K76AG074940-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.